HERTICAD 440mg Injection is a targeted monoclonal antibody therapy containing Trastuzumab, specifically formulated for the treatment of HER2-positive breast and gastric cancers. HER2 (human epidermal growth factor receptor 2) is a protein that promotes the rapid growth of cancer cells in certain types of cancer. HERTICAD works by binding to HER2 receptors on cancer cells, blocking their activity, and activating the immune system to destroy these cells.

Key Features

• Targets HER2-positive cancer cells with precision.
• Slows tumor growth and prevents further disease progression.
• Can be combined with chemotherapy or other therapies for enhanced effectiveness.
• Administered intravenously under medical supervision.

Indications

HERTICAD 440mg Injection is indicated for:

• HER2-positive breast cancer (early-stage and metastatic).
• HER2-positive gastric or gastroesophageal junction cancer.

Dosage and Administration

HERTICAD 440mg Injection is administered as an intravenous infusion by a healthcare professional. The dosage and frequency depend on the patient’s weight, condition, and treatment plan prescribed by the doctor.

Precautions

• Inform your doctor about any heart conditions, infections, or previous cancer treatments before starting therapy.
• Regular monitoring of heart function and overall health is essential during the course of treatment.
• HERTICAD is not recommended during pregnancy, as it may harm the fetus. Women of childbearing age should use effective contraception during treatment and for at least 7 months after the final dose.

Benefits

HERTICAD 440mg Injection provides a targeted approach to managing HER2-positive cancers, improving survival rates, reducing tumor burden, and enhancing the quality of life for patients.

FAQs:

1. What is HERTICAD 440mg Injection used for?

HERTICAD 440mg Injection is used to treat HER2-positive breast cancer (both early-stage and metastatic) and HER2-positive gastric or gastroesophageal junction cancer. It targets the HER2 protein, blocking its activity to slow tumor growth and improve survival rates.

2. How does HERTICAD 440mg Injection work?

HERTICAD contains Trastuzumab, a monoclonal antibody that binds to HER2 receptors on cancer cells. By blocking HER2 activity, it prevents tumor growth and stimulates the immune system to destroy the affected cancer cells.

3. Can HERTICAD 440mg Injection be used with other treatments?

Yes, HERTICAD is often used in combination with chemotherapy, hormonal therapy, or other targeted therapies to enhance its effectiveness in treating HER2-positive cancers.

4. What precautions should I take before receiving HERTICAD 440mg Injection?

Before starting therapy, inform your doctor about any existing heart conditions, infections, or previous cancer treatments. Regular monitoring of heart function and overall health is necessary during the course of treatment.

5. Can HERTICAD 440mg Injection cause heart problems?

In some cases, HERTICAD may lead to heart-related side effects, such as reduced heart function or heart failure. Your doctor will monitor your heart health throughout the treatment process.

6. Can HERTICAD 440mg Injection be self-administered?

No, HERTICAD must be administered by a healthcare professional in a clinical setting to ensure proper dosage, infusion rate, and monitoring for potential reactions during the infusion process.

7. How long will I need to receive HERTICAD 440mg Injection?

The duration of treatment depends on the type and stage of cancer being treated. For early-stage breast cancer, treatment may last up to a year, while for metastatic cancers, it may continue as long as the treatment remains effective.